Trevi Therapeutics TRVI 深 滬
已收盤 02-06 16:00:00 美东时间
11.46
+0.520
+4.75%
華盛通- 最 高11.81
- 今 開11.19
- 成交量 159.50万股
- 最 低 11.005
- 昨 收 10.94
- 總市值 14.70亿
- 52周最高 14.39
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 3.9625
- 委 比 -7.55%
- 總股本 1.28亿
- 歷史最高 14.39
- 量 比 1.04
- 振 幅 7.36%
- 歷史最低 0.46
- 每 手 1
- 風險率 2.61%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Trevi Therapeutics' Phase 2b CORAL Trial Results Published In JAMA Shows Nalbuphine ER Significantly Reduces Chronic Cough, With Over 60% Of Patients Achieving 50% Cough Reduction
Statistically-significant reduction in the relative change from baseline in 24-hour objective cough frequency observed across all dose groups of nalbuphine ER at Week 6 with statistically-significant cough reduction as
01-23 01:33
Trevi Therapeutics Reports Positive Phase 2b Results for Nalbuphine ER in IPF Chronic Cough Trial
Trevi Therapeutics Reports Positive Phase 2b Results for Nalbuphine ER in IPF Chronic Cough Trial Trevi Therapeutics Inc. announced the publication of key results from its Phase 2b CORAL trial evaluating oral nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibr
01-23 01:30
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
Trevi Therapeutics Intends To Start Phase 2b Study In Participants With Refractory Chronic Cough In H1 2026, Company's Chronic Cough In Idiopathic Pulmonary Fibrosis Granted End-Of-Phase 2 Meeting With FDA
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients
01-08 20:38
美股大行评级 | 绩后评级出炉！联邦快递获多家大行上调目标价；耐克遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Pyxis Oncology"买入"评级，目标价从5美元升至7美元；Stifel：维持Oculis Holding"买入"评级，目标价从35美元升至40美元
2025-12-22 15:05
Stifel Maintains Buy on Trevi Therapeutics, Raises Price Target to $18
Stifel analyst Annabel Samimy maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises the price target from $15 to $18.
2025-12-19 22:54
Trevi Therapeutics appoints new CFO
Trevi Therapeutics (TRVI) named David Hastings as its next chief financial officer, effective January 6, 2026. Hastings prior roles include CFO positions at Arbutus, Unilife, and Incyte. Hastings curr...
2025-12-04 20:43
Trevi Therapeutics Appoints Veteran Finance Leader David Hastings as New CFO Starting January 2026
Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with
2025-12-04 20:33
美股牛股 | Arrowhead制药飙升23%，行业首个微粒血症商用药物获FDA批准；DeFi大涨20%
Arrowhead制药飙升23%，行业首个微粒血症商用药物获FDA批准，最新财报强劲超预期；DeFi大涨20%，公司宣布QCAD数字信托获批为加拿大首个合规的加元稳定币>>
2025-11-27 16:04
